YOYasumasa Ohyagi

Yasumasa Ohyagi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yasumasa Ohyagi has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Morphologic variation of the circle of Willis is associated with cognitive impairment in a general population: The J-SHIPP study

    by Yoko Okada, Yasuharu Tabara, Katsuhiko Kohara, Satoko Takei, Masayuki Ochi, Michiya Igase, Yasumasa Ohyagi


  • Open Access

    A case of immunocompetent intracranial cryptococcoma in which intraoperative rapid pathological diagnosis and polymerase chain reaction led to early treatment: What to know to avoid misdiagnosis as brain tumor

    by Saho Fujishita, Akihiro Inoue, Hideaki Watanabe, Masahiro Nishikawa, Mashio Taniwaki, Sayaka Matsumoto, Masayuki Ochi, Koichiro Suemori, Akira Watanabe, Riko Kitazawa, et al.

    Background: Cryptococcal infections of the central nervous system are infrequent in immunocompetent hosts and usually present as meningitis. However, a fungal mass called a cryptococcoma may form, requiring caution in therapeutic intervention. Here, we report a rare case in which treatment of intraventricular cryptococcoma in an immunocompetent patient was facilitated by rapid pathological diagnosis. Case Description: A 58-year-old previously healthy man was admitted to our hospital with fever, headache, and gradually worsening hearing loss over 1 month. Cerebrospinal fluid analysis showed moderately elevated levels of protein and lymphocytic cells and decreased glucose. In addition, β2-microglobulin was highly elevated. Magnetic resonance imaging showed homogeneously enhanced lesions in lateral ventricles of the left and right hemispheres and the subarachnoid space, and 18F-fluorodeoxyglucose positron emission tomography revealed abnormal uptake corresponding to the lesion. A surgical excision was performed to achieve a definitive diagnosis. Intraoperative rapid pathology, including immunohistochemistry (IHC), yielded negative results for malignant tumor, suggesting the possibility of inflammatory granuloma. Additional targeted pathological diagnosis was immediately performed. Paraffin-embedded histopathological examination showed fibrocaseous granuloma and numerous fungal spores. Cryptococcus neoformans within the granuloma were suggested by Fontana–Masson and Grocott staining and confirmed by polymerase chain reaction (PCR), leading to a diagnosis of cryptococcoma. Antifungal agents were started 3 days postoperatively. The patient has since been doing well, with no recurrence. Conclusion: This pathology can be difficult to distinguish from a brain tumor, so early pathological diagnosis, including rapid pathology with IHC and PCR, may be crucial.


  • Bioimpedance phase angle is independently associated with myosteatosis: The Shizuoka study

    by Michitaka Kato, Yoko Okada, Wataru Nakano, Daisuke Takagi, Masayuki Ochi, Yasumasa Ohyagi, Michiya Igase, Yasuharu Tabara


  • Open Access

    Reliability of cerebral vasoreactivity assessment from the submandibular window

    by Yoko Okada, Kensuke Senzaki, Shiori Kuwagaki, Shu Kondo, Satoko I. Takei, Shiroh Miura, Masayuki Ochi, Hirofumi Ochi, Michiya Igase, Yasumasa Ohyagi

    Background and Purpose: Transcranial Doppler (TCD) is a noninvasive and effective technique for the measurement of cerebrovascular function. Measurement of breath holding index (BHI) in the middle cerebral artery is commonly performed to determine cerebrovascular reactivity. Nevertheless, a notable drawback of TCD is the absence of a transtemporal acoustic bone window. The submandibular window offers an alternative way to measure BHI. Here, we studied the diagnostic accuracy of cerebrovascular reactivity (CVR) in the internal carotid artery (ICA) as measured from the submandibular window. Methods: Twenty-five volunteers (13 male, 12 female) with sufficient temporal acoustic bone windows were assessed. BHI was measured by mean blood velocities before and after breath holding. The correlation of BHI measured in ICA (BHIi) and ipsilateral middle cerebral artery (BHIm) was assessed. Results: The mean age of the participants was 39.9 ± 13.7 years. The mean BHIm and BHIi values were 0.93 ± 0.29 and 0.92 ± 0.32, respectively. Spearman’s correlation coefficient between BHIm and BHIi was 0.665 (p = 0.0003). The cutoff point of the BHIi value for CVR impairment determined by BHIm was 0.71 (sensitivity 80.0%, specificity 80.0%). Conclusion: Measuring BHI from the submandibular window may be a useful procedure in the case of temporal bone window insufficiency.


  • Open Access

    Insulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model

    by Tomohiro Imamura, Yuki T. Yanagihara, Yasumasa Ohyagi, Norimichi Nakamura, Kyoko M. Iinuma, Ryo Yamasaki, Hirohide Asai, Masahiro Maeda, Kazuma Murakami, Kazuhiro Irie, et al.


  • Open Access

    Insulin signaling as a therapeutic target in Alzheimer’s disease: Efficacy of apomorphine

    by Yasumasa Ohyagi, Satoko I. Takei

    Alzheimer's disease has recently been characterized as “diabetes of the brain” or “type 3 diabetes.” Although recent clinical trials targeting amyloid β‐protein have been unsuccessful, glucose‐insulin metabolism in the brain may provide an alternative therapeutic target. In this review, we focus on three related topics: (a) how peripheral and brain insulin resistance interact with each other; (b) brain insulin resistance as a promising therapeutic target for Alzheimer's disease and anti‐diabetic drugs as potentially effective drugs; and (c) apomorphine as a novel drug that improves neuronal insulin signaling. Although apomorphine is a dopamine receptor agonist, studies in our laboratory revealed a novel effect, promoting intracellular amyloid β degradation and improving memory function in an Alzheimer's disease mouse model. Recently, we demonstrated that apomorphine treatment improved neuronal insulin resistance and activated insulin‐degrading enzyme, a major amyloid β‐degrading enzyme. In addition, we confirmed the efficacy of apomorphine for some Alzheimer's disease patients. In this context, combined treatment involving anti‐diabetic drugs and apomorphine may provide an effective therapeutic approach for Alzheimer's disease.


  • Sporadic Japanese case of adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia caused by a de novo p.Phe849del mutation in CSF1R

    by Kensuke Senzaki, Shiroh Miura, Masayuki Ochi, Takeaki Katoh, Yoko Okada, Sayaka Matsumoto, Akira Shiraoka, Hirofumi Ochi, Michiya Igase, Riko Kitazawa, et al.


  • Therapeutic Strategies for Alzheimer’s Disease in the View of Diabetes Mellitus

    by Yasumasa Ohyagi, Katsue Miyoshi, Norimichi Nakamura

    Recently, Alzheimer’s disease (AD) is understood as “diabetes of the brain” or “type 3 diabetes.” Recent clinical trials of anti-amyloid β-protein (Aβ) therapies have not proved to be successful. Thus, glucose-insulin metabolism in the brain is thought to be an alternative therapeutic target. Various types of antidiabetic drugs such as insulin, thiazolidinediones, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, biguanides, and others have been reported to be effective on cognitive impairment in animal models and patients with DM or AD. Here, recent reports are reviewed. While we identified apomorphine (APO) as a novel drug that promoted intracellular Aβ degradation and improved memory function in an AD mouse model, more recently, we have revealed that APO treatment improves neuronal insulin resistance and activates insulin-degrading enzyme (IDE), a major Aβ-degrading enzyme. In this context, recovery of impaired insulin signaling in AD neurons may be a promising therapeutic strategy for AD dementia.


  • Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimer’s Disease

    by Norimichi Nakamura, Yasumasa Ohyagi, Tomohiro Imamura, Yuki T. Yanagihara, Kyoko M. Iinuma, Naoko Soejima, Hiroyuki Murai, Ryo Yamasaki, Jun-Ichi Kira

    Apomorphine (APO) promotes intraneuronal amyloid-β (Aβ) degradation and improves memory function in an Alzheimer’s disease (AD) model, 3xTg-AD mice. Since insulin resistance is increased in AD neurons, we investigated the effects of APO on brain insulin resistance in 3xTg-AD mice at early and late stages. After 1-month subcutaneous injection of Apokyn ® to 3xTg-AD mice at 6 or 12 months of age, memory function was significantly improved in both age groups. Protein levels of insulin-degrading enzyme (IDE), which is linked to insulin signaling and degrades Aβ, significantly increased in the 3xTg-AD mice brain compared with non-transgenic mice, and were further increased by APO. Protein levels of two types of serine-phosphorylated insulin receptor substrate-1 (IRS-1), pS 616 and pS 636/639 , significantly decreased following APO treatment in the 13-month-old 3xTg-AD mice brain, suggesting improved brain insulin resistance. Immunostaining of the IDE, pS 616 and pS 636/639 IRS-1 demonstrated similar changes due to APO treatment. Thus, brain insulin resistance is considered an important therapeutic target in AD, and APO may provide improved neuronal insulin resistance.


  • Open Access

    Office-based simple frailty score and central blood pressure predict mild cognitive impairment in an apparently healthy Japanese population: J-SHIPP study

    by Maya Ohara, Katsuhiko Kohara, Yoko Okada, Masayuki Ochi, Tokihisa Nagai, Yasumasa Ohyagi, Yasuharu Tabara, Michiya Igase

    Frailty is associated with cognitive impairment and can be used to identify people at high risk for dementia. We developed a simple frailty (SF) score using a combination of low hand grip strength (<32.5 kg in men, <19.5 kg in women), and short one-leg standing time (<20 seconds). These can be easily measured in the clinician’s office when seeing patients. We investigated the possible association between SF score and mild cognitive impairment (MCI) in a cross-sectional study with 838 independent middle-aged to elderly participants (319 men, mean age 65.1years). In total, 118 participants were diagnosed with MCI. A SF score of 2 was significantly associated with the presence of MCI (odds ratio 4.6, 95% confidence interval: 1.9–6.9, p = 0.0001) even after adjustment for age and sex. Stepwise regression analyses showed that a SF score of 2 was associated with the presence of MCI, independently of central pulse pressure and silent cerebral infarcts. These findings indicate that the SF score is a useful frailty parameter to predict MCI in an apparently independent population.